INTER-EWING-1

Ewing Sarcoma (ES) is a rare cancer of the bone and soft tissue that is most commonly diagnosed in adolescents and young adults. Current treatment protocols involve chemotherapy, surgery and/ or radiotherapy, which produces a 5-year survival rate 65-75%. There is a possibility of life-long side effects, including further disease. Patients that are diagnosed when the cancer has already spread (metastasised) or have experienced a recurrence of their disease have a much lower chance of survival.

This study will examine if changing treatment at three key points can improve survival for patients diagnosed with ES. These changes are:

1. Combining a new drug (regorafenib) with chemotherapy
2. Refining radiotherapy treatment/doses
3. Adding further chemotherapy at the end of treatment.

Disease Stage – Newly diagnosed

Patient Age Range – 2 to 50 years of age

Trial sponsors

National – ANZCHOG

International – University of Birmingham

Sites

Perth Children’s Hospital
Peter MacCallum Cancer Centre